(Q35539743)

8 August 2017

title

Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. (English)

1 reference

8 August 2017

0 references

1 reference

1 reference

5

J L Blumer

1 reference

8 August 2017

M D Reed

1

1 reference

8 August 2017

R C Stern

series ordinal

2

1 reference

8 August 2017

C A O'Brien

series ordinal

3

1 reference

8 August 2017

D A Crenshaw

series ordinal

4

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 May 1987

1 reference

Antimicrobial Agents and Chemotherapy

8 August 2017

published in

1 reference

8 August 2017

volume

31

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

698-702

1 reference

Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Pharmacokinetics of Methicillin in Patients with Cystic Fibrosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174817

Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period

26 September 2018

1 reference

12 December 2020

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

1 reference

12 December 2020

Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis

1 reference

12 December 2020

Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response

1 reference

12 December 2020

Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis

1 reference

12 December 2020

Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study

1 reference

12 December 2020

Ceftazidime disposition in acute and stable cystic fibrosis

1 reference

12 December 2020

Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.31.5.698

1 reference

release_ix7pjhqsjzhtrfrgvopy4hw74i

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ix7pjhqsjzhtrfrgvopy4hw74i

24 November 2022

mapped directly with Wikidata item

PMC publication ID

174817

1 reference

8 August 2017

1 reference